104 related articles for article (PubMed ID: 36451418)
21. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract][Full Text] [Related]
22. Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition.
Barsouk A; Elghawy O; Stone S; Singh A
Anticancer Drugs; 2024 Apr; ():. PubMed ID: 38696710
[TBL] [Abstract][Full Text] [Related]
23. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.
O'Leary C; Xu W; Pavlakis N; Richard D; O'Byrne K
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31058838
[TBL] [Abstract][Full Text] [Related]
24. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
[TBL] [Abstract][Full Text] [Related]
25. Identification and Validation of Noncanonical RET Fusions in Non-Small-Cell Lung Cancer through DNA and RNA Sequencing.
Xiang C; Guo L; Zhao R; Teng H; Wang Y; Xiong L; Han Y
J Mol Diagn; 2022 Apr; 24(4):374-385. PubMed ID: 35063667
[TBL] [Abstract][Full Text] [Related]
26. Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
Clark L; Fisher G; Brook S; Patel S; Arkenau HT
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201460
[TBL] [Abstract][Full Text] [Related]
27. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
Belli C; Penault-Llorca F; Ladanyi M; Normanno N; Scoazec JY; Lacroix L; Reis-Filho JS; Subbiah V; Gainor JF; Endris V; Repetto M; Drilon A; Scarpa A; André F; Douillard JY; Curigliano G
Ann Oncol; 2021 Mar; 32(3):337-350. PubMed ID: 33455880
[TBL] [Abstract][Full Text] [Related]
28. MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
Riedel R; Fassunke J; Scheel AH; Scheffler M; Heydt C; Nogova L; Michels S; Fischer RN; Eisert A; Scharpenseel H; John F; Ruge L; Schaufler D; Siemanowski J; Ihle MA; Wagener-Ryczek S; Pappesch R; Rehker J; Bunck A; Kobe C; Keil F; Merkelbach-Bruse S; Büttner R; Wolf J
J Thorac Oncol; 2024 Jan; 19(1):160-165. PubMed ID: 37429463
[TBL] [Abstract][Full Text] [Related]
29.
Conde E; Hernandez S; Rodriguez Carrillo JL; Martinez R; Alonso M; Curto D; Jimenez B; Caminoa A; Benito A; Garrido P; Clave S; Arriola E; Esteban-Rodriguez I; De Castro J; Sansano I; Felip E; Rojo F; Dómine M; Abdulkader I; Garcia-Gonzalez J; Teixido C; Reguart N; Compañ D; Insa A; Mancheño N; Palanca S; Juan-Vidal O; Baixeras N; Nadal E; Cebollero M; Calles A; Martin P; Salas C; Provencio M; Aranda I; Massuti B; Lopez-Vilaro L; Majem M; Paz-Ares L; Lopez-Rios F
JTO Clin Res Rep; 2024 Apr; 5(4):100653. PubMed ID: 38525319
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.
Ali MA; Shah SS; Ali R; Bajwa SF; Rehman S; Anwar A; Anwar MY; Saeed M; Mirza N; Aiman W
Cancer Invest; 2023 Sep; 41(8):739-749. PubMed ID: 37782113
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report.
de Jong LAW; Sparidans RW; van den Heuvel MM
Case Rep Oncol; 2023; 16(1):1579-1585. PubMed ID: 38094038
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.
Aldea M; Marinello A; Guyon D; Gazzah A; Barlesi F; Planchard D; Besse B
JAMA Oncol; 2023 Nov; 9(11):1583-1584. PubMed ID: 37707807
[TBL] [Abstract][Full Text] [Related]
33. Selpercatinib and capmatinib combination promotes sustained complete response in novel
Leite CA; Carvalho RP; da Costa FM; Medeiros AK; Schutz FA; William WN
Front Oncol; 2023; 13():1264231. PubMed ID: 37876974
[No Abstract] [Full Text] [Related]
34. Salvage Therapy With Selpercatinib for
d'Arienzo PD; Cunningham N; O'Sullivan H; Grieco C; Patel V; Popat S
JTO Clin Res Rep; 2023 Dec; 4(12):100581. PubMed ID: 38034820
[TBL] [Abstract][Full Text] [Related]
35.
Desilets A; Repetto M; Yang SR; Sherman EJ; Drilon A
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627175
[No Abstract] [Full Text] [Related]
36. In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC".
Murciano-Goroff YR; Lin ST; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):e52-e53. PubMed ID: 37087124
[No Abstract] [Full Text] [Related]
37. Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory,
Calles A; Arregui M; Suárez-González J; García-Martos M; Márquez-Rodas I; Álvarez R; Martin M
JCO Precis Oncol; 2023 Sep; 7():e2300321. PubMed ID: 37922409
[No Abstract] [Full Text] [Related]
38. Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC.
De Carlo E; Bertoli E; Chimienti E; Del Conte A; Bearz A
J Thorac Oncol; 2023 Feb; 18(2):e11-e13. PubMed ID: 36682840
[No Abstract] [Full Text] [Related]
39. Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer.
Huang Y; Dai S; Yin W; Luo F; Li Y
Onco Targets Ther; 2023; 16():1015-1020. PubMed ID: 38050583
[TBL] [Abstract][Full Text] [Related]
40. Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.
Szymczak S; Szpurka A; Lu ZH; Dempsey JA
Thyroid; 2023 Dec; 33(12):1493-1495. PubMed ID: 37376747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
